Correction
1 Aug 2014: The PLOS ONE Staff (2014) Correction: Critical Role of TLR2 and MyD88 for Functional Response of Macrophages to a Group IIA-Secreted Phospholipase A2 from Snake Venom. PLOS ONE 9(8): e105241. https://doi.org/10.1371/journal.pone.0105241 View correction
Figures
Abstract
The snake venom MT-III is a group IIA secreted phospholipase A2 (sPLA2) enzyme with functional and structural similarities with mammalian pro-inflammatory sPLA2s of the same group. Previously, we demonstrated that MT-III directly activates the innate inflammatory response of macrophages, including release of inflammatory mediators and formation of lipid droplets (LDs). However, the mechanisms coordinating these processes remain unclear. In the present study, by using TLR2−/− or MyD88−/− or C57BL/6 (WT) male mice, we report that TLR2 and MyD88 signaling have a critical role in MT-III-induced inflammatory response in macrophages. MT-III caused a marked release of PGE2, PGD2, PGJ2, IL-1β and IL-10 and increased the number of LDs in WT macrophages. In MT-III-stimulated TLR2−/− macrophages, formation of LDs and release of eicosanoids and cytokines were abrogated. In MyD88−/− macrophages, MT-III-induced release of PGE2, IL-1β and IL-10 was abrogated, but release of PGD2 and PGJ2 was maintained. In addition, COX-2 protein expression seen in MT-III-stimulated WT macrophages was abolished in both TLR2−/− and MyD88−/− cells, while perilipin 2 expression was abolished only in MyD88−/− cells. We further demonstrated a reduction of saturated, monounsaturated and polyunsaturated fatty acids and a release of the TLR2 agonists palmitic and oleic acid from MT-III-stimulated WT macrophages compared with WT control cells, thus suggesting these fatty acids as major messengers for MT-III-induced engagement of TLR2/MyD88 signaling. Collectively, our findings identify for the first time a TLR2 and MyD88-dependent mechanism that underlies group IIA sPLA2-induced inflammatory response in macrophages.
Citation: Leiguez E, Giannotti KC, Moreira V, Matsubara MH, Gutiérrez JM, Lomonte B, et al. (2014) Critical Role of TLR2 and MyD88 for Functional Response of Macrophages to a Group IIA-Secreted Phospholipase A2 from Snake Venom. PLoS ONE 9(4): e93741. https://doi.org/10.1371/journal.pone.0093741
Editor: Patricia T. Bozza, Fundação Oswaldo Cruz, Brazil
Received: November 21, 2013; Accepted: March 6, 2014; Published: April 9, 2014
Copyright: © 2014 Leiguez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This investigation was supported by research grants from FAPESP, São Paulo, Brazil (www.fapesp.br), grants 11/21341-5 and 10/06345-1, INCTTOX, São Paulo, Brazil (www.incttox.com.br), grant 573790/2008-6, CNPq PQ, Brazil (www.cnpq.br), grant 306920/2011-5, Brazil, Spanish Ministery of Science and Innovation, Spain (http://web.micinn.es/), grant BFU2010-18826. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Secreted phospholipases A2 (sPLA2s) are enzymes that hydrolyse glycerophospholipids at the sn-2 position of the glycerol backbone in a calcium-dependent manner, releasing fatty acids and lysophospholipids. These enzymes are members of the PLA2 superfamily, which is widely distributed in nature, and 15 groups and subgroups have been described, including five categories termed secreted PLA2, cytosolic PLA2, Ca2+ independent PLA2, the platelet-activating factor acetylhydrolase, and lysosomal PLA2 [1]. Among them, group IIA sPLA2 includes mammalian inflammatory-type and Viperid snake venom sPLA2s [2], [3]. Besides their relevant role in cell membrane physiology, mammalian group IIA sPLA2s are recognized as important paracrine and autocrine players in inflammatory processes by their ability to release fatty acids from cell membranes, leading to subsequent production of pro-inflammatory mediators such as prostaglandins, leukotrienes [1]. Accordingly, sPLA2 enzymes, particularly group IIA sPLA2s, have been implicated in the pathophysiology of several inflammatory diseases, such as atherosclerosis, inflammatory bowel disease, asthma and arthritis [4], [5], [6].
Besides structural homology, snake venom group IIA sPLA2s share functional features with mammalian group IIA sPLA2s, owing to their ability to induce inflammatory events in both in vivo and in vitro experimental models [7]. sPLA2s are abundant components in the proteomes of snake venoms from Bothrops genus [8] and have been associated with the prominent local inflammatory effects induced by these venoms. An Asp49 sPLA2, named myotoxin-III (MT- III), has been purified from Bothrops asper snake venom [9]. This group IIA sPLA2 has been reported to induce inflammatory events in in vivo experimental models [10], [11]. Furthermore, this venom sPLA2 exhibits the ability to directly activate inflammatory functions in isolated macrophages, such as increased phagocytic capacity, release of cytokines [11], [12], up-regulation of lipid mediator cascade, with release of prostaglandins [13], and increased formation of lipid droplets (LDs) [14], which are organelles implicated in the differentiation of macrophages into foam cells. However, the initial steps leading to this sPLA2-induced activation of macrophages are still unknown.
Macrophages are pivotal cells in innate immune responses. Activation of these cells initiates cascades of events that lead to acute inflammatory processes and the switch from the acute to the resolutive phase of inflammation, by releasing resolutive mediators, such as PGJ2 and IL-10 [15], [16]. In addition, macrophages are relevant cells in the development of many chronic inflammatory diseases, such as atherosclerosis. Macrophages loaded with LDs, termed foam cells, constitute an early hallmark of atherosclerotic lesion formation and a major cell source of inflammatory mediators [17], [18].
The macrophage innate response is initiated by activation of diverse membrane recognition receptors, such as the Toll-like receptors (TLRs). Nowadays, at least 13 TLRs have been described, each of them with a degree of specificity for various endogenous and exogenous ligands, eliciting different, but sometimes overlapping, immune responses [19], [20]. In inflammatory processes, recognition of pathogen-associated molecular patterns (PAMPs) by TLRs except TLR3 activates cell-signaling pathways mediated by the MyD88 [20]. Other kinds of stimuli, named endogenous damage-associated molecular patterns (DAMPs), are also capable of activating MyD88-dependent innate immune signaling by TLRs [21]. Some of the well- characterized DAMPs include: fibronectins [22], heat-shock proteins [23], pro-inflammatory cytokines from the monocyte-macrophage system [24], and free fatty acids (FFA) [25]. Among the TLRs, TLR2 constitutes a molecular link between elevated circulating FFA and inflammation [26]–[28]. TLR2 binds lipid-based structures via their long-chain saturated FFA moieties [25], [29], triggering inflammatory responses through MyD88 signaling [30]. Although TLRs are critical receptors directing specific inflammatory programs in macrophages, the involvement of TLR2 and MyD88 adaptor molecule signaling pathways in the activation of macrophages by group IIA sPLA2 remains unknown. The understanding of the mechanism(s) involved in sPLA2s-induced activation of in a pivotal immune innate cell, such as the macrophage, shall provide valuable information on new targets to confront the inflammatory diseases where group IIA sPLA2s enzymes are involved.
In the present study the involvement of TLR2 and MyD88 adaptor molecule in the signaling cascade (inflammatory signaling) elicited by MT-III in macrophages was investigated. To test this possibility, the effects of MT-III in macrophages from wild-type (WT) C57BL/6 mice, TLR2 gene knockout (TLR2−/−) mice and MyD88 gene knockout (MyD88−/−) were evaluated in terms of PGE2, PGD2, PGJ2, IL-1β and IL-10 biosynthesis, LDs formation, COX-2 and perilipin-2 expression and release of free fatty acids. Herein, we present the first evidence that TLR2 and MyD88 adaptor molecule are implicated in the inflammatory response triggered by a group IIA sPLA2 enzyme in macrophages. Engagement of TLR2/MyD88 signaling pathway by the venom sPLA2 MT-III coordinates events related to both initiation and resolution of the inflammatory response in macrophages. Our observations also suggest that saturated free fatty acids are major agonists for engagement of TLR2/MyD88 pathway induced by this group IIA sPLA2.
Materials and Methods
Ethics Statement
This study includes experiments with macrophages collected from pathogen-free 5-week-old wild type (WT), MyD88−/− and TLR2−/− mice (all on a C57BL/6 genetic background). These animals were bred in animal facilities at the University of São Paulo and were housed in a temperature-controlled room (22–24°C) with a 12 h light-dark cycle and fresh water and food ad libitum until used. All experimental procedures involving these animals were performed in accordance with the procedures laid down by the Universities Federation for Animal Welfare and were approved by the Animal Experimentation Ethics Committee of University of São Paulo (São Paulo, Brazil; Reference No 94/2010).
Chemicals and Reagents
Hema-3 stain from Biochemical Sciences (Swedesboro, NJ, USA). MTT and L-glutamine were obtained from USB (Cleveland, OH, USA). E-toxate LAL kit and mouse mAb anti-β-actin was purchased from Sigma-Aldrich (St. Louis, MO, USA) and guinea pig polyclonal antibody anti- mouse perilipin-2 (PLIN2) from Research Diagnostics (Flanders, NJ, USA). PGE2 and PGD2 enzyme immunoassay kits and polyclonal antibodies against COX-2 were purchased from Cayman Company, Ann Arbor, MI, USA. 15-deoxy-Δ12,14– prostaglandin J2 (PGJ2) and IL-10 and IL-1β enzyme immunoassay kits were purchased from Enzo Life Sciences (Ann Arbor, MI, USA) and eBioscience, Inc. (San Diego, CA, USA), respectively. Secondary antibodies, anti- mouse and anti-guinea pig, conjugated to HRP and nitrocellulose membrane, were obtained from GE Healthcare (Buckinghamshire, UK). Gentamicin was purchased from Schering-Plough (Whitehouse Station, NJ, USA) and DMSO from Amresco (Solon, OH, USA). RPMI 1640, thiocarbohydrazide, and Osmium tetroxide (OsO4) were purchased from Sigma-Aldrich and RPMI from Life Technologies (São Paulo, SP, Brazil). Chloroform and methanol (HPLC grade) were purchased from Fisher Scientific (Hampton, NH), and [1–14C] palmitic acid and oleic acid from Perkin Elmer (Waltham, MA). Silicagel thin layer chromatography plates were purchased from Macherey-Nagel (Düren, Germany). Thioglycolate was obtained from Merck (Darmstadt, Germany) and all salts used were purchased from Sigma-Aldrich.
Phospholipase A2 (PLA2)
Aspartate-49 sPLA2 named MT-III (Uniprot accession no.: P20474) from B. asper venom was purified by ion-exchange chromatography on CM-Sephadex C-25, using a KCl gradient from 0 to 0.75 M at pH 7.0 as described [2], followed by RP-HPLC on a semipreparative C8 column (Vydac; 10×250 mm, 5 μm particle size) eluted at a flow rate of 2.5 ml/min with a gradient of acetonitrile (0–70%, containing 0.1% trifluoroacetic acid) over 30 min. Homogeneity was verified by SDS-PAGE, run under reducing conditions, in which a single band of ∼14 kDa was observed. The complete amino acid sequence of this enzyme has been described previously [31], [32]. The absence of endotoxin contamination in the MT-III batches used was demonstrated by performing the quantitative LAL test [33], which revealed undetectable levels of endotoxin (<0.125 EU/mL).
Macrophages Harvesting and Stimulation
Animals were killed under CO2 atmosphere and cells were then harvested by washing peritoneal cavities with 3 mL apyrogenic phosphate buffered saline (PBS), pH 7.2. Aliquots of the washes were used for total cell counts in a Neubauer chamber, after dilution (1∶20, v/v) in Turk solution (0.2% crystal violet dye in 30% acetic acid). Differential cell counts were performed on smears stained with Hema3. More than 95% of the cell population consisted of macrophages, as determined by conventional morphological criteria. The remaining wash volumes were centrifuged at 129×g for 6 min (4°C), supernatants were discarded and cell pellets were appropriately diluted and maintained in serum-free RPMI 1640 medium, supplemented with 2 mM L-glutamine and 40 μg/mL gentamicin sulfate at 37°C with 5% CO2, and processed according to the experimental protocols used, as follows: 1) 1×106 macrophages/well were seeded in 12 wells culture plates and maintained in culture medium for 24 h before stimulation, and then used for Western blotting analysis of COX-2 and perilipin-2 protein expression; 2) 2×105 macrophages, harvested 4 days after i.p. injection of 1 mL 3% thioglycolate, were seeded on glass coverslips and incubated in culture medium for 30 min for adhesion, followed by washing with PBS, and then used for LDs evaluation; 3) 1×107 macrophages were seeded in cell culture dish, maintained in culture medium for 18 h, and used for gas chromatography/mass spectrometry analysis of fatty acid methyl esters; 4) 2×105 macrophages/well were seeded in 12 well culture plates, maintained with culture medium for 30 min for adhesion and then incubated with exogenous [1–14C] Oleic or [1–14C] Palmitic acid (1 μM; 0.25 μCi/ml) for 18 h at 37°C. Cells were then scraped with 0.1% Triton X-100 in PBS and supernatants were removed and total 14C-radioactivity levels were determined by scintillation counting. After each of the above described procedures, cells were stimulated with MT-III diluted in RPMI 1640 medium in a final concentration of 0.4 μM or RPMI 1640 medium alone (control) for selected periods of time and maintained at 37°C in a humidified atmosphere (5% CO2).
Quantification of Eicosanoids and Cytokines
Prostaglandins (PGE2, PGD2 and PGJ2) and cytokines (IL-1β and IL-10) were quantified in supernatants from macrophages cultures by using commercially available enzyme immune assay kits, performed according to instructions of the manufacturer.
Lipid Droplet (LD) Staining and Quantification
Analysis of LD numbers was performed in osmium-stained cells. In brief, macrophages adhered to glass coverslips were fixed in 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.2) for 15 min and stained with OsO4. The coverslips were then rinsed in 0.1 M phosphate buffer, stained with 1% OsO4 (30 min), rinsed in deionized H2O, immersed in 1.0% thiocarbohydrazide (5 min), rinsed again in 0.1 M phosphate buffer, re-stained with 1% OsO4 (3 min), rinsed with H2O, and then dried and mounted [42]. The morphology of the fixed cells was observed, and round intracellular osmiophilic structures were identified as LDs, which were then counted under phase-contrast microscopy using the 100×objective lens in 50 consecutively scanned leukocytes in each coverslip.
Western Blotting for COX-2 and Perilipin-2
COX-2 and perilipin-2 protein levels in cultured macrophages were detected by Western blotting. Aliquots of MT-III-stimulated and non-stimulated cells (1.5×106 cells) were lysed with 100 μL sample buffer (0.5 M Tris-HCl, pH 6.8, 20% SDS, 1% glycerol, 1 M β-mercapto ethanol, 0.1% bromophenol blue) and boiled for 10 min. Samples were resolved by SDS-PAGE on 10% bis-acrylamide gels overlaid with a 5% stacking gel. Proteins were then transferred to nitrocellulose membranes using a Mini Trans-Blot (Bio-Rad Laboratories, Richmond, CA, USA). The membranes were blocked for 1 h with 5% nonfat dry milk in Tris-buffered saline (TBS) (20 mM Tris, 100 mM NaCl, and 0.5% Tween 20, pH 7.2), and incubated with primary antibodies against COX-2 (1∶1000 dilution), perilipin-2 (1∶2000) and β-actin (1∶3000) for 1 h. They were then washed and incubated with the appropriate secondary antibody conjugated to horseradish peroxidase. The immunonereactive bands were detected by the entry-level peroxidase substrate for enhanced chemiluminescence (ECL), according to the instructions of the manufacturer (GE Healthcare). Band densities were quantified with a GS 700 densitometer (Bio- Rad Laboratories) using the image analysis software Molecular Analyst (Bio-Rad Laboratories).
Gas Chromatography/mass Spectrometry Analysis of Fatty Acid Methyl Esters
A cell extract was used and, before extraction, 10 nmol of 1,2,3-triheptadecanoylglycerol was added as internal standard. Then, total lipids were extracted according to the Bligh and Dyer method [34], and glycerolipids were transmethylated with 500 μl of 0.5 M KOH in methanol for 60 min at 37°C. For neutralization, 500 μl of 0.5 M HCl were added and the extraction of fatty acid methyl esters was performed with 1 ml of n-hexane twice. Analysis of fatty acid methyl esters was carried out in a Agilent 7890A gas chromatograph coupled to an Agilent 5975C mass--selective detector operated in electron impact mode (EI, 70 eV), equipped with an Agilent 7693 autosampler and an Agilent DB23 column (60 m length×250 μm internal diameter×0.15 μm film thickness) under the following conditions: oven temperature was held at 50°C for 1 min, then increased to 175°C at a rate of 25°C/min, then increased to 215°C at a rate of 1.5°C/min, and the final ramp being reached at 235°C at a rate of 10°C/min. The final temperature was maintained for 5 min, and the run time was 39.67 min. Data analysis was carried out with the Agilent G1701EA MSD Productivity Chemstation software, revision E.02.00, and the quantification of fatty acid methyl esters was achieved by integration of chromatographic peaks comparing with authentic analytical standards [35], [36]. The fatty acids evaluated are indicated below in table 1.
Quantification of Fatty Acids (FA) Released
The cells were placed in serum-free medium and exposed to exogenous [14C] Oleic or [14C] Palmitic acid (1 μM; 0.25 μCi/ml) for 18 h at 37°C. Afterward, the cells were washed four times with PBS containing 0.5% albumin to remove the fatty acids that had not been incorporated, and next stimulated with MT-III or RPMI medium only (control) for 6 h. Cells were scraped with 0.1% Triton X-100 in PBS, supernatants were removed, and total 14C-radioactivity levels were determined by scintillation counting.
Statistical Analysis
Data are expressed as the mean ± standard error of mean (S.E.M) of at least three animals. Multiple comparisons among groups were performed using one-way ANOVA and Tukey test as a post-test. Differences between experimental groups were considered significant for P-values <0.05. All statistic tests were performed using Prism version 5 software (GraphPad, San Diego, CA).
Results
Prostaglandin Production Induced by MT-III Requires Distinct TLR Signaling Pathways
Prostaglandins are produced in abundance at sites of inflammation and regulate many aspects of the inflammatory response. Prostaglandins such as PGE2 and PGD2 have well-defined roles in acute inflammation, such as the regulation of blood flow and edema formation, cytokine generation, and leukocyte migration [37], [38]. In contrast to these lipid mediators, PGJ2, which is a PGD2-derived prostanoid, has been described as a resolutive mediator, which is involved in the switch from the acute into the regenerative phases of inflammatory processes [16]. We have previously reported that the sPLA2 MT-III elicits the biosynthesis of prostaglandins in isolated peritoneal macrophages [13]. These relevant cells of the innate immune system sense danger signals via recognition receptors such as TLRs, and then initiate a coordinated inflammatory response. However, whether TLR pathways, particularly TLR2 and MyD88 adaptor molecule activation, are required for this and other MT-III-induced effects in macrophages is unknown, and deserve further investigation. Therefore, we initially evaluated the involvement of TLR2 and MyD88 signaling in MT-III-induced PGE2, PGD2 and PGJ2 production in TLR2- and MyD88- deficient macrophages. Results presented in Figure 1 (A–C) show that PGE2 levels were significantly increased in MT-III-stimulated macrophages collected from WT mice. This MT-III- induced PGE2 release was impaired in macrophages obtained either from TLR2−/− or MyD88−/−mice. Notably, sPLA2 MT-III failed to induce PGD2 and PGJ2 production in TLR2−/−, but did induce production of these mediators in MyD88−/− macrophages when compared with MT-III- stimulated WT cells. These observations prompted us to consider that TLR2 signaling is engaged for the biosynthesis of PGE2, PGD2 and PGJ2 in macrophages under stimuli by MT-III. However, the TLR2 via MyD88 adaptor molecule pathway operates only for biosynthesis of PGE2, whereas production of PGD2 and PGJ2 occurs through an adaptor molecule other than MyD88. Of note, these findings further suggest that upon activation by the sPLA2 MT-III, TLR2 and MyD88 signaling pathways can coordinate macrophage responses related to both the development and resolution steps of inflammation.
Wild type (WT) or TLR2−/− or MyD88−/− peritoneal macrophages were incubated with MT-III (0.4 μM) or RPMI (control) for 6 h. PGE2 (A), PGD2 (B) and PGJ2 (C) concentrations were quantified in culture supernatants by EIA commercial kits; (D) Western blotting immunoreactive bands of COX-2 and β-actin (loading control) representative of at least three samples/experimental group; (E) Densitometric analysis of immunoreactive COX-2 band intensities. Densities (in arbitrary units) were normalized with those of β-actin. Results are expressed as mean ± SEM from 3–6 animals. *p<0.05 as compared with control cells; #p<0.05 as compared with MT-III-stimulated cells.
Up-regulation of COX-2 Protein Expression Induced by MT-III is Dependent on TLR2 via MyD88 Signaling Pathway
Activation of TLR2 via MyD88-mediated signaling leads to activation of transcription factors such as NF-kB, AP-1 and IRF, which in turn play an important role in gene transcription of several molecules involved in the inflammatory response, such as cytokines and cyclooxygenase-2 (COX-2) [39]–[42]. Prostaglandins are produced by cyclooxygenases, which occur in constitutive (COX-1) and inducible (COX-2) forms [6]. We have previously demonstrated that MT-III up-regulates COX-2 protein expression in peritoneal macrophages and that this isoform is responsible for the increased levels of prostaglandins induced by this sPLA2 [13]. However, the involvement of TLR2 and MyD88 signaling pathway in this process is unknown. The potential role of TLR2 and MyD88 signaling in MT-III-induced COX-2 protein expression was then analyzed. Figure 1 (D) shows that TLR2−/− and MyD88−/− macrophages stimulated by MT-III did not present the increased COX-2 protein expression seen in MT-III-stimulated WT macrophages. These data clearly indicate that TLR2 and MyD88 are essential to this effect induced by the sPLA2 MT-III, constituting a key step in the onset of MT-III-induced activation of macrophages. Participation of MyD88 signaling in this MT-III-induced effect is consistentwith previous reports by others that activation of this adaptor molecule signals for gene expression of COX-2 [19], [43].
TLR2 via MyD88 Signaling Pathway is Required for MT-III-induced Production of IL-1β and IL-10 in Macrophages
IL-1β and IL-10 are relevant mediators involved in triggering and down-regulation of inflammatory processes, respectively [44], [45]. Despite the distinct roles played by these two cytokines in inflammation, the production of these mediators has been shown to be regulated by TLR2 and MyD88 signaling [46]. The ability of MT-III to induce the release of inflammatory cytokines, such as IL-1β, has been previously demonstrated [12]. However, whether this MT-III- induced event is coordinated by TLR2 and MyD88 pathways is unknown. Moreover, neither the ability of MT-III to induce release of IL-10 by macrophages nor the participation of TLR2 and MyD88 pathways in this effect has been investigated. We therefore explored the potential role of TLR2 and MyD88 signaling in MT-III-induced synthesis of these cytokines. As demonstrated in Figure 2 (A–B), stimulation of WT macrophages with MT-III induced a significant release of IL- 1β and IL-10 from these cells. However, stimulation of TLR2−/− and MyD88−/− macrophages by MT-III did not result in an increased release of these two cytokines as compared with MT-III- stimulated WT macrophages. These data confirm previous observations on the ability of MT-III to induce the release of IL-1β and additionally evidenced the capacity of this sPLA2 to induce the release of IL-10. Furthermore, these data implicate the TLR2 via MyD88 signaling pathway in the generation of IL-1β and IL-10 induced by MT-III in macrophages.
Wild type (WT) or TLR2−/− or MyD88−/− peritoneal macrophages were incubated with MT-III (0.4 μM) or RPMI (control) for 6 h. IL-1β (A) and IL-10 (B) concentrations were quantified in culture supernatants by EIA commercial kits. Results are expressed as mean ± SEM from 3–6 animals. *p<0.05 as compared with control group; #p<0.05 as compared with MT-III- stimulated WT cells.
TLR2 via MyD88 is a Critical Pathway for MT-III-induced LD Formation
It has been demonstrated that LDs formation in leukocytes is a highly regulated event that depends on the interaction of cellular receptors with their ligands. These organelles were shown to be involved in the synthesis of inflammatory mediators and are markers of leukocyte activation [47], [48]. Moreover, the role of TLRs-mediated pathogen recognition and activation in the mechanism of LDs formation has been demonstrated by others [48], [49]. We have recently shown that MT-III induces the formation of LDs in macrophages [14]. However, the mechanisms underlying this MT-III-induced effect remain unclear. To further understand this issue we investigated the involvement of TLR2 and MyD88 signaling. As demonstrated in Figure 3A, the sPLA2 MT-III failed to induce LDs formation in macrophages from both TLR2−/− and MyD88−/− mice when compared with macrophages from WT mice, at both time intervals evaluated. These findings identify TLR2 via MyD88 adaptor molecule as an essential signaling pathway regulating LD biogenesis induced by the venom sPLA2 MT-III in macrophages. Considering that LD-laden macrophages constitute the foam cells seen at the sites of atherosclerotic lesion, in which levels of the sPLA2s are increased, our present findings suggest that activation of TLR2/MyD88-mediated signaling pathway is likely to be an important mechanism that accounts for foam cell formation stimulated by group IIA sPLA2s.
Wild type (WT) or TLR2−/− or MyD88−/− peritoneal macrophages were incubated either with MT-III (0.4 μM) or RPMI (control) for 6 or 12 h. (A) Lipid droplets numbers; (B) Western blotting immunoreactive bands of perilipin-2 (PLIN2) and β-actin (loading control); (C) Densitometric analysis of immunoreactive PLIN2 band intensities. Densities (in arbitrary units) were normalized with those of β-actin. Results are expressed as mean ± SEM from 3–6 animals. *p<0.05 as compared with control group; #p<0.05 as compared with MT- III- stimulated WT cells.
Requirement of TLR2 and/or MyD88 Signaling for MT-III-induced Perilipin-2 up- Regulation and Mobilization
Perilipin-2 has long been reported as a pivotal protein for neutral lipid accumulation that serves as scaffolding during LD formation in diverse cell types, including macrophages [50], [51]. This protein is constitutively and ubiquitously expressed in macrophages as a major component of intracellular LDs [50], [52]–[54]. Moreover, the expression of perilin-2 can be up-regulated during inflammatory processes [51], [55], [56]. Consistent with these properties, perilipin-2 has been used as a marker of lipid loading and LD assembly in inflammatory cells [57]. Accumulating evidence indicates that activation of the Toll like receptors triggers foam cell formation and increase of perilipin-2 protein expression [49], [58], [59]. In macrophages, MT-III has been shown to up- regulate perilipin-2 protein expression and to trigger mobilization of constitutive perilipin-2 to form new LDs in macrophages [14]. On this basis, we assessed the involvement of TLR2 and MyD88 in perilipin-2 protein expression induced by MT-III in macrophages for 6 h. As demonstrated in Figure 3B, following MT-III stimulation of WT macrophages, there is a significant increase of perilipin-2 protein expression in comparison with RPMI-stimulated WT macrophages. This increased protein expression was observed in TLR2−/− macrophages stimulated by MT-III when compared with WT macrophages. Conversely, MyD88−/− macrophages stimulated by this sPLA2 were unable to up-regulate perilipin-2 protein expression as compared to WT macrophages. These data indicate that perilipin-2 protein expression induced by MT-III is dependent on MyD88 pathway, but not on TLR2 activation. Next we evaluated the potential role of TLR2 and MyD88 signaling in subcellular mobilization of perilipin-2 induced by MT-III. As illustrated in Figure 4, WT macrophages stimulated by MT-III exhibited strong fluorescent staining (green) for perilipin-2, with a punctate cytoplasmic pattern, which was absent in RPMI-stimulated control cells. Fluorescent Nile Red-labeled LDs were also visualized after MT-III-induced stimulation and were virtually absent in non-stimulated WT macrophages. After stimulation with MT-III, cytoplasmic-stained perilipin-2 matched perfectly with Nile Red- marked neutral lipid inclusions. As expected, no significant staining was detected in WT control macrophages. However, this phenomenon was not observed in macrophages from TLR2−/− or MyD88−/− mice, demonstrating that perilipin-2 subcellular distribution induced by MT-III is dependent on TLR2 and MyD88 signaling pathway in a tight correlation with the regulation of MT-III-induced LD formation by TLR2/MyD88 pathway.
Wild Type (WT), TLR2−/− or MyD88−/− peritoneal macrophages were incubated with RPMI (control) or MT-III (0.4 μM) for 6 h and labeled for both lipid droplets (fluorescent Nile red) and anti-PLIN2 (FITC-conjugated immunocomplex). Merged image shows localization of PLIN2 to lipid droplets in WT macrophages. Cell nuclei were stained with propidium iodide. IgG control was included and showed negative stain. The micrographs are representative of at least three samples/experimental group.
MT-III Releases Free Fatty Acids from Macrophages
To better understand the mechanisms underlying activation of TLR2 and MyD88 signaling by MT-III in macrophages, we analyzed the ability of this sPLA2 to generate free fatty acids, which are recognized as efficient agonists of TLRs, mainly TLR2 [25], [28], [29], [60]. The total fatty acid profile was then analyzed in MT-III-stimulated macrophages by measuring fatty acid methyl esters using gas chromatography mass spectrometry coupled. Figure 5A shows that stimulation of WT macrophages with the sPLA2 MT-III resulted in a remarkable reduction of fatty acids presumably due to the action of this enzyme on membrane phospholipids. Large decreases were observed in palmitic, stearic, oleic, and particularly in arachidonic acid, which clearly generated a pool of intracellular free fatty acids, that must be reorganized in order to keep intact the cellular homeostasis. To accomplish this, two of the possible underlying mechanisms are: 1) lipid droplet formation and 2) excretion of fatty acids into the extracellular environment. In order to test this latter hypothesis, we previously added labeled free fatty acids (palmitic and oleic acid) to the peritoneal macrophage culture and let them to incorporate; then we determined the blink per minute in a radioactivity counter. Figure 5B shows that higher amounts of palmitic and oleic acids were found in culture supernatants of MT-III-stimulated WT macrophages than in controls, suggesting that these FFA may consequently stimulate the Toll like receptors by an autocrine mechanism.
(A) The profile of major fatty acids in peritoneal macrophages from WT mice stimulated with MT-III (0.4 μM) (gray bars) or RPMI (control) (open bars) for 6 h was determined by GC- MS after converting the glyceryl fatty acid into fatty acid methyl esters. (B) Peritoneal macrophages were incubated with 1 μM [14C]palmitic acid or (C) [14C] oleic acid for 18 h. Afterward, [14C]palmitic acid or [14C] oleic acid incorporation was measured in macrophages and their supernatants 6 h after stimulation with either MT-III or RPMI (control) as described in Materials and Methods. The 14C radioactivity incorporated is expressed as a percentage of the radioactivity originally added to the cells. Results are expressed as means ± SEM from 3–6 animals. *p<0.05 as compared with the corresponding control.
Discussion
Group IIA secreted PLA2 enzymes are considered important players in inflammatory process owing to their ability to induce the biosynthesis of second messengers that stimulate innate responses of inflammatory cells, including macrophages. As TLRs are recognized to trigger a pro-inflammatory program in macrophages and respond to exogenous molecules and host-derived endogenous ligands [20], [61], in the present study we investigated the participation of TLR2 and MyD88 adaptor molecule in the stimulatory effects of the venom sPLA2 MT-III in macrophages.
The data presented herein indicate a major role for TLR2 in MT-III-induced production of inflammatory mediators by macrophages, since the production of PGE2, PGD2 and PGJ2 induced by MT-III was abrogated in TLR2−/− macrophages, indicating the engagement of TLR2 upon stimulus by this sPLA2. To our knowledge, this is the first demonstration that TLR2 pathway is activated by a secreted PLA2 enzyme leading to biosynthesis of lipid mediators. Reports from literature have shown that endogenous Group V and Group X sPLA2s are capable to amplify signaling through TLR2 and TLR4/MyD88 in cells stimulated by the pathogen- activated molecular patterns Pam3CSK4 and LPS, leading to biosynthesis of eicosanoids in mast cells and macrophages, respectively [31], [69]. Furthermore, we found that the adaptor molecule MyD88 plays a role in MT-III-induced production of PGE2, since the release of this mediator was abrogated in MyD88−/− macrophages stimulated by MT-III. However, the increment of PGD2 and PGJ2 induced by MT-III was not altered in MyD88−/− macrophages, suggesting that their synthesis is triggered through an adaptor molecule other than MyD88, in the present experimental condition. This is the first demonstration that a secreted group IIA PLA2 directly activates macrophages to release PGJ2. Noteworthy, the present findings also evidence, for the first time, that the production of a resolutive mediator is regulated by the TLR2 pathway.
A previous report of our group demonstrated that, similarly to mammalian GIIA sPLA2s [70], MT-III up-regulates COX-2 protein expression, a critical enzyme for PGs production in macrophages [13]. We herein extended the understanding of this mechanism by showing that MT-III up-regulates COX-2 expression via TLR2 and MyD88 signaling pathways in macrophages, based on the inability of TLR2−/− and MyD88−/− macrophages to express COX-2 in response to MT-III stimulus. Taking these data into account, and considering results showing that MyD88 adaptor molecule is involved in MT-III-induced production of PGE2, but not PGD2 or PGJ2, it is suggested that COX-2 is the major PGE2 biosynthetic pathway, whereas production of PGD2 and PGJ2 may be associated to both COX-2 and COX-1 biosynthetic pathways. Consistent with this hypothesis, a previous report has shown the ability of MT-III to induce an increment in the activity of COX-1 along with expression of COX-2 in macrophages [13].
The ability of sPLA2s, including MT-III, to induce the release of cytokines has been previously demonstrated [12], [71]. The data presented herein demonstrate that this sPLA2 induces the release of IL-10 and IL-1β in a process mediated by TLR2/MyD88 signaling pathway. These findings also bring additional evidence that engagement of TLR2/MyD88 signaling pathway coordinates both the acute and resolutive responses in macrophages upon stimulation by the sPLA2 MT-III. Furthermore, increased IL-10 biosynthesis, observed in MT-III-stimulated WT macrophages, suggests that in our experimental conditions this cytokine regulates the synthesis of PGE2 via TLR2/MyD88 pathway activation, as a tight regulation of PGE2 biosynthesis by IL-10 has been previously demonstrated in macrophages [62]–[64].
LDs are cytoplasmic inclusions found in numerous immune cells associated with inflammation [51], [54], [65], such as foam macrophages, which are major cells of atherosclerotic lesions [66]. We recently demonstrated that MT-III induces LDs formation, recruitment and increased expression of the LD scaffold protein perilipin-2 in macrophages [14]. The results obtained herein demonstrate, for the first time, that TLR2 and MyD88 are essential elements for LD formation induced by MT-III, since TLR2−/− and MyD88−/− macrophages failed to respond with increased numbers of LDs. These results are in agreement with previous reports by others showing that TLR2/MyD88 pathway is involved in LDs formation in leukocytes [47]–[49]. On the other hand, our data further demonstrate that TLR2 deletion does not affect the ability of MT-III to induce a significant increase of perilipin-2 protein expression, but inhibits its capacity to mobilize constitutive perilipin-2 in the cytosol, evidencing that although not signaling for up regulation of perilipin-2 expression, this receptor is engaged for its recruitment, triggering an important mechanism for LD formation. In contrast, MyD88 deleted cells blocked MT-III- induced expression and mobilization of perilipin-2, implying the participation of this adaptor molecule in this effect. Therefore, activation of a TLR other than TLR2 is involved in MT-III- induced expression of perilipin-2. To our knowledge, this is the first demonstration of participation of TLR2 and MyD88 pathways in the mechanisms leading to LDs formation induced by group IIA sPLA2, and that MyD88 is a crucial adaptor molecule mediating perilipin-2 expression and mobilization induced by this class of enzymes. Experimental studies have previously demonstrated that TLRs, particularly TLR2 via MyD88-dependent pathway, have relevant roles in the differentiation of recruited monocytes into lipid-laden macrophages (foam cells), and ultimately to the development of atherosclerotic lesions [67], [68]. Considering the reported increased expression of group IIA sPLA2s at the site of atherosclerotic lesions [9], our present findings may shed light on the early mechanisms involved in the ability of sPLA2s to induce formation of foam macrophages.
The mechanisms by which MT-III activates TLR2 were not presently investigated. It has been shown that a free fatty acid (FFA)-rich microenvironment leads to the activation of TLR2 [28], [60]. Moreover, there are data demonstrating that products of cleavage of membrane phospholipids by sPLA2s, including saturated fatty acids, lysophosphatidylcholine and lysophosphatidylserine, are able to activate this receptor [60], [72], [73], [74]. In this context, we herein demonstrate that MT-III reduced the levels of saturated FFA, such as palmitic and stearic acid, as well as monounsaturated and polyunsaturated fatty acids in macrophages. Decreased levels of both palmitic and oleic acids correlated with increased amounts of these fatty acids in the extracellular medium, indicating that they are released from macrophages upon the action of MT-III, thus allowing their interaction with surface membrane receptors. On this basis, we suggest that, in the present experimental conditions, saturated FFAs resulting from the catalytic action of MT-III on membrane phospholipids are autocrine ligands for TLR2, which then triggers an inflammatory program in macrophages, via pathways dependent on MyD88. However, participation of lysophospholipids in this mechanism cannot be ruled out. In support of our hypothesis, when catalytic activity of MT-III is inhibited, increments in LD formation are abrogated [14]. In addition, the involvement of TLR2 in the release of the cytokines IL-1β and IL-10 induced by minimally modified LDL in macrophages has been previously described [46]. In conclusion, we provide evidence of a critical role for TLR2 and MyD88 adaptor molecule in mediating sPLA2-induced inflammatory responses in macrophages. We have shown for the first time that the TLR2 and Myd88 adaptor molecule are involved in cellular and molecular inflammatory processes triggered by the venom sPLA2 MT-III in macrophages, that include the production of eicosanoids and cytokines and the formation of LDs, as well as an increased expression of COX-2 and perilipin-2 mobilization and expression. Interestingly, these findings indicate that TLR2, via MyD88 adaptor molecule, links sPLA2s with LD and foam cell formation. Moreover, we speculate that saturated free fatty acids released by MT-III enzyme activity from phospholipids in the macrophage membrane, are autocrinally recognized by TLR2, thereby initiating an inflammatory signaling cascade in macrophages. Altogether, these findings amplify the current knowledge on the mechanisms involved in the stimulatory effects of Group IIA sPLA2s in macrophages, specially those that trigger inflammatory events, including foam cell formation, which is a hallmark of atherosclerosis. Such a mechanism may contribute to the identification of useful new targets for the development of novel therapeutic strategies for inflammatory diseases related to lipid imbalance where group IIA sPLA2s enzymes are involved.
Acknowledgments
The authors acknowledge Renata Hage do Amaral for technical assistance and Dr. Henrique Krambeck Rofatto (Butantan Institute), for supporting confocal laser scanning microscopy analysis.
Author Contributions
Conceived and designed the experiments: CT EL JB JMG BL. Performed the experiments: EL KCG VM MHM JPR. Analyzed the data: CT EL KCG VM MHM JPR. Contributed reagents/materials/analysis tools: CT JB JMG BL. Wrote the paper: EL CT JB JMG BL.
References
- 1. Schaloske RH, Dennis EA (2006) The phospholipase A2 superfamily and its group numbering system. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1761: 1246–1259.
- 2. Kaiser II, Gutierrez JM, Plummer D, Aird SD, Odell GV (1990) The amino acid sequence of a myotoxic phospholipase from the venom of Bothrops asper. Arch Biochem Biophys 278: 319–325.
- 3.
Kini RM (1997) Phospholipase A2 - A complex multifuncional protein puzzle. In: Venom phospholipase A2 enzymes. structure, function and mechanism. New York: Wiley J and Sons, 1.
- 4. Yedgar S, Cohen Y, Shoseyov D (2006) Control of phospholipase A2 activities for the treatment of inflammatory conditions. Biochim Biophys Acta 1761: 1373–1382.
- 5. Triggiani M, Granata F, Giannattasio G, Marone G (2005) Secretory phospholipases A2 in inflammatory and allergic diseases: not just enzymes. J Allergy Clin Immunol 116: 1000–1006.
- 6. Karabina SA, Gora S, Atout R, Ninio E (2010) Extracellular phospholipases in atherosclerosis. Biochimie 92: 594–600.
- 7. Teixeira C, Cury Y, Moreira V, Picolob G, Chaves F Huwiler (2009) AG (2009) Inflammation induced by Bothrops asper venom. Toxicon 54: 988–997.
- 8. Calvete JJ (2011) Proteomics in Venom Research: a Focus on PLA2 Molecules. Acta Chim Slov 58: 629–637.
- 9. Gutiérrez JM, Lomonte B (1995) Phospholipase A2 myotoxins from Bothrops snake venoms. Toxicon 33: 1405–1424.
- 10. Chaves F, Leon G, Alvarado VH, Gutierrez JM (1998) Pharmacological modulation of edema induced by Lys-49 and Asp-49 myotoxic phospholipases A2 isolated from the venom of the snake Bothrops asper (terciopelo). Toxicon 36: 1861–1869.
- 11. Zuliani JP, Fernandes CM, Zamuner SR, Gutierrez JM, Teixeira CF (2005) Inflammatory events induced by Lys-49 and Asp-49 phospholipases A2 isolated from Bothrops asper snake venom: role of catalytic activity. Toxicon 45: 335–346.
- 12. Zuliani JP, Gutierrez JM, Casais e Silva LL, Coccuzzo Sampaio S, Lomonte B, et al. (2005) Activation of cellular functions in macrophages by venom secretory Asp-49 and Lys-49 phospholipases A(2). Toxicon 46: 523–532.
- 13. Moreira V, Gutierrez JM, Soares AM, Zamuner SR, Purgatto E, et al. (2008) Secretory phospholipases A(2) isolated from Bothrops asper and from Crotalus durissus terrificus snake venoms induce distinct mechanisms for biosynthesis of prostaglandins E2 and D2 and expression of cyclooxygenases. Toxicon 52: 428–439.
- 14. Leiguez E, Zuliani JP, Cianciarullo AM, Fernandes CM, Gutierrez JM, et al. (2011) A group IIA-secreted phospholipase A2 from snake venom induces lipid body formation in macrophages: the roles of intracellular phospholipases A2 and distinct signaling pathways. J Leukoc Biol 90: 155–166.
- 15. Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958–969.
- 16. Surh YJ, Na HK, Park JM, Lee HN, Kim W, et al. (2011) 15-Deoxy-Delta(1)(2),(1)(4)-prostaglandin J(2), an electrophilic lipid mediator of anti-inflammatory and pro-resolving signaling. Biochem Pharmacol 82: 1335–1351.
- 17. Ghesquiere SA, Gijbels MJ, Anthonsen M, van Gorp PJ, van der Made I, et al. (2005) Macrophage-specific overexpression of group IIa sPLA2 increases atherosclerosis and enhances collagen deposition. J Lipid Res 46: 201–210.
- 18. Choudhury RP, Lee JM, Greaves DR (2005) Mechanisms of disease: macrophage- derived foam cells emerging as therapeutic targets in atherosclerosis. Nat Clin Pract Cardiovasc Med 2: 309–315.
- 19. O’Neill LA (2008) The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 226: 10–18.
- 20. Takeuchi O, Akira S (2010) Pattern recognition receptors and inflammation. Cell 140: 805–820.
- 21. Dinarello, C A (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27: 519–550.
- 22. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, et al. (2001) 3rd (2001) The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 276: 10229–10233.
- 23. Wallin RP, Lundqvist A, More SH, von Bonin A, Kiessling R, et al. (2002) Heat-shock proteins as activators of the innate immune system. Trends Immunol 23: 130–135.
- 24. Yu L, Wang L, Chen S (2012) Exogenous or endogenous Toll-like receptor ligands: which is the MVP in tumorigenesis? Cell Mol Life Sci 69: 935–949.
- 25. Lee JY, Zhao L, Youn HS, Weatherill AR, Tapping R, et al. (2004) Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll- like receptor 6 or 1. J Biol Chem 279: 16971–16979.
- 26. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, et al. (2006) TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116: 3015–3025.
- 27. Song MJ, Kim KH, Yoon JM, Kim JB (2006) Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem Biophys Res Commun 346: 739–745.
- 28. Nguyen MT, Favelyukis S, Nguyen AK, Reichart D, Scott PA, et al. (2007) A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem 282: 35279–35292.
- 29. Lee JY, Sohn KH, Rhee SH, Hwang D (2001) Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem 276: 16683–16689.
- 30. Boni-Schnetzler M, Boller S, Debray S, Bouzakri K, Meier DT, et al. (2009) Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology. 150: 5218–5229.
- 31. Kikawada E, Bonventre JV, Arm JP (2007) Group V secretory PLA2 regulates TLR2- dependent eicosanoid generation in mouse mast cells through amplification of ERK and cPLA2alpha activation. Blood 110: 561–567.
- 32. Diaz-Oreiro C, Gutierrez JM (1997) Chemical modification of histidine and lysine residues of myotoxic phospholipases A2 isolated from Bothrops asper and Bothrops godmani snake venoms: effects on enzymatic and pharmacological properties. Toxicon 35: 241–252.
- 33. Takayama K, Mitchell DH, Din ZZ, Mukerjee P, Li C, et al. (1994) Monomeric Re lipopolysaccharide from Escherichia coli is more active than the aggregated form in the Limulus amebocyte lysate assay and in inducing Egr-1 mRNA in murine peritoneal macrophages. J Biol Chem 269: 2241–2244.
- 34. Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol 37: 911–917.
- 35. Astudillo AM, Pérez-Chacón G, Balgoma D, Gil-de-Gómez L, Ruipérez V, et al. (2011) Influence of cellular arachidonic acid levels on phospholipid remodeling and CoA-independent transacylase activity in human monocytes and U937 cells. Biochim. Biophys. Acta 1811: 97–103.
- 36. Guijas C, Perez-Chacon G, Astudillo AM, Rubio JM, Gil-de-Gomez L, et al. (2012) Simultaneous activation of p38 and JNK by arachidonic acid stimulates the cytosolic phospholipase A2-dependent synthesis of lipid droplets in human monocytes. J Lipid Res 53: 2343–2354.
- 37. Hata AN, Breyer RM (2004) Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 103: 147–166.
- 38. Hirata T, Narumiya S (2012) Prostanoids as regulators of innate and adaptive immunity. Adv Immunol 116: 143–174.
- 39. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, et al. (1998) Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9: 143–150.
- 40. Casanova JL, Abel L, Quintana-Murci L (2011) Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Annu Rev Immunol 29: 447–491.
- 41. Lin SC, Lo YC, Wu H (2010) Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature 465: 885–890.
- 42. Loures FV, Pina A, Felonato M, Feriotti C, de Araujo EF, et al. (2011) MyD88 signaling is required for efficient innate and adaptive immune responses to Paracoccidioides brasiliensis infection. Infect Immun 79: 2470–2480.
- 43. McGettrick AF, O’Neill LA (2007) Toll-like receptors: key activators of leucocytes and regulator of haematopoiesis. Br J Haematol 139: 185–193.
- 44. Sims JE, Smith DE (2010) The IL-1 family: regulators of immunity. Nat Rev Immunol 10: 89–102.
- 45.
Han X, Boisvert WA (2012) The Role of IL-10 in Atherosclerosis, Atherogenesis, Prof. Sampath Parthasarathy (Ed.), ISBN: 978–953–307–992–9, InTech, Available from: http://www.intechopen.com/books/atherogenesis/the-role-of-il-10-in-atherosclerosis.
- 46. Chavez-Sanchez L, Chavez-Rueda K, Legorreta-Haquet MV, Zenteno E, Ledesma-Soto Y, et al. (2010) The activation of CD14, TLR4, and TLR2 by mmLDL induces IL-1beta, IL-6, and IL-10 secretion in human monocytes and macrophages. Lipids Health Dis 9: 117.
- 47. Pacheco P, Bozza FA, Gomes RN, Bozza M, Weller PF, et al. (2002) Lipopolysaccharide-induced leukocyte lipid body formation in vivo: innate immunity elicited intracellular Loci involved in eicosanoid metabolism. J Immunol 169: 6498–6506.
- 48. D’Avila H, Melo RC, Parreira GG, Werneck-Barroso E, Castro-Faria-Neto HC, et al. (2006) Mycobacterium bovis bacillus Calmette-Guerin induces TLR2-mediated formation of lipid bodies: intracellular domains for eicosanoid synthesis in vivo. J Immunol 176: 3087–3097.
- 49. Nicolaou G, Erridge C (2010) Toll-like receptor-dependent lipid body formation in macrophage foam cell formation. Curr Opin Lipidol 21: 427–433.
- 50. Brasaemle DL, Barber T, Wolins NE, Serrero G, Blanchette-Mackie EJ, et al. (1997) Adipose differentiation-related protein is an ubiquitously expressed lipid storage droplet- associated protein. J Lipid Res 38: 2249–2263.
- 51. Larigauderie G, Furman C, Jaye M, Lasselin C, Copin C, et al. (2004) Adipophilin enhances lipid accumulation and prevents lipid efflux from THP-1 macrophages: potential role in atherogenesis. Arterioscler Thromb Vasc Biol 24: 504–510.
- 52. Heid HW, Moll R, Schwetlick I, Rackwitz HR, Keenan TW (1998) Adipophilin is a specific marker of lipid accumulation in diverse cell types and diseases. Cell Tissue Res 294: 309–321.
- 53. Persson J, Degerman E, Nilsson J, Lindholm MW (2007) Perilipin and adipophilin expression in lipid loaded macrophages. Biochem Biophys Res Commun 363: 1020–1026.
- 54. Robenek H, Robenek MJ, Troyer D (2005) PAT family proteins pervade lipid droplet cores. J Lipid Res 46: 1331–1338.
- 55. Corsini E, Sheasgreen J, Marinovich M, Galli CL (2002) Use of differential display- polymerase chain reaction to identify genes selectively modulated by chemical allergens in reconstituted human epidermis. Toxicol In Vitro 16: 427–431.
- 56. Sarov-Blat L, Kiss RS, Haidar B, Kavaslar N, Jaye M, et al. (2007) Predominance of a proinflammatory phenotype in monocyte-derived macrophages from subjects with low plasma HDL-cholesterol. Arterioscler Thromb Vasc Biol 27: 1115–1122.
- 57. Brasaemle DL, Dolios G, Shapiro L, Wang R (2004) Proteomic analysis of proteins associated with lipid droplets of basal and lipolytically stimulated 3T3-L1 adipocytes. J Biol Chem 279: 46835–46842.
- 58. Feingold KR, Kazemi MR, Magra AL, McDonald CM, Chui LG, et al. (2010) ADRP/ADFP and Mal1 expression are increased in macrophages treated with TLR agonists. Atherosclerosis 209: 81–88.
- 59. Wang J, Si Y, Wu C, Sun L, Ma Y, et al. (2012) Lipopolysaccharide promotes lipid accumulation in human adventitial fibroblasts via TLR4-NF-kappaB pathway. Lipids Health Dis 11: 139.
- 60. Huang S, Rutkowsky JM, Snodgrass RG, Ono-Moore KD, Schneider DA, et al. (2012) Saturated fatty acids activate TLR-mediated proinflammatory signaling pathways. J Lipid Res 53: 2002–2013.
- 61. Iwata H, Nagai R (2012) Novel immune signals and atherosclerosis. Curr Atheroscler Rep 14: 484–490.
- 62. MacKenzie KF, Clark K, Naqvi S, McGuire VA, Noehren G, et al. (2013) PGE(2) induces macrophage IL-10 production and a regulatory-like phenotype via a protein kinase A-SIK-CRTC3 pathway. J Immunol 190: 565–577.
- 63. Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, et al. (2009) Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 15: 42–49.
- 64. Heusinkveld M, de Vos van Steenwijk PJ, Goedemans R, Ramwadhdoebe TH, Gorter A, et al. (2011) M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol 187: 1157–1165.
- 65. Krahmer N, Farese Jr RV, Walther TC (2013) Balancing the fat: lipid droplets and human disease. EMBO Mol Med 5: 905–915.
- 66. Ley K, Miller YI, Hedrick CC (2011) Monocyte and macrophage dynamics during atherogenesis. Arterioscler Thromb Vasc Biol 31: 1506–1516.
- 67. Cole JE, Mitra AT, Monaco C (2010) Treating atherosclerosis: the potential of Toll-like receptors as therapeutic targets. Expert Rev Cardiovasc Ther 8: 1619–1635.
- 68. Liu Y, Yu H, Zhang Y, Zhao Y (2008) TLRs are important inflammatory factors in atherosclerosis and may be a therapeutic target. Med Hypotheses 70: 314–316.
- 69. Shridas P, Bailey WM, Talbott KR, Oslund RC, Gelb MH, et al. (2011) Group X secretory phospholipase A2 enhances TLR4 signaling in macrophages. J Immunol 187: 482–9.
- 70. Bryant KJ, Bidgood MJ, Lei PW, Taberner M, Salom C, et al. (2011) A bifunctional role for group IIA secreted phospholipase A2 in human rheumatoid fibroblast-like synoviocyte arachidonic acid metabolism. J Biol Chem 286: 2492–503.
- 71. Granata F, Petraroli A, Boilard E, Bezzine S, Bollinger J, et al. (2005) Activation of cytokine production by secreted phospholipase A2 in human lung macrophages expressing the M-type receptor. J Immunol 174: 464–474.
- 72. Magalhães K, Almeida PE, Atella G, Maya-Monteiro CM, Castro-Faria-Neto H, et al. (2010) Schistosomal-derived lysophosphatidylcholine are involved in eosinophil activation and recruitment through Toll-like receptor-2-dependent mechanisms. J Infect Dis. 202: 1369–79.
- 73. Frasch SC, Bratton DL (2012) Emerging roles for lysophosphatidylserine in resolution of inflammation. Prog Lipid Res. 51: 199–207.
- 74. Carneiro AB, Iaciura BM, Nohara LL, Lopes CD, Veas EM, et al. (2013) Lysophosphatidylcholine triggers TLR2- and TLR4-mediated signaling pathways but counteracts LPS-induced NO synthesis in peritoneal macrophages by inhibiting NF-κB translocation and MAPK/ERK phosphorylation. PLoS One 8: e76233.